Skip Navigation

Cardiovascular Research 2003 57(1):178-185; doi:10.1016/S0008-6363(02)00615-6
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Royen, N
Right arrow Articles by Piek, J.J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Royen, N
Right arrow Articles by Piek, J.J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits

N van Royena,b,*, I Hoeferb, I Buschmannb, S Kostinc, M Voskuila, Ch Bodeb, W Schaperc and J.J Pieka

aDepartment of Cardiology, University of Amsterdam, Amsterdam, The Netherlands
bDepartment of Cardiology, University of Freiburg, Freiburg, Germany
cDepartment of Experimental Cardiology, Max Planck Institute, Bad Nauheim, Germany

* Corresponding author. Tel.: +49-761-270-6349; fax: +49-761-503-4950. vanroyen{at}med1.ukl.uni-freiburg.de

Objective: The objective of our study was to quantify the arteriogenic potency of Monocyte Chemoattractant Protein-1 (MCP-1) under hyperlipidemic conditions. Additionally, we aimed to determine the effects of locally applied MCP-1 on systemic serum lipid levels as well as on atherosclerosis. Methods: A total of sixty-four Watanabe rabbits was treated with either low dose MCP-1 (1 µg/kg/week), high dose MCP-1 (3.3 µg/kg/week) or PBS as a control substance. Substances were applied directly into the collateral circulation via an osmotic minipump with the catheter placed in the proximal stump of the ligated femoral artery. Either 1 week or 6 months after initiation of the treatment X-ray angiography was performed as well as measurements of collateral conductance using fluorescent microspheres. The extent of atherosclerosis was quantified in whole aortas using Sudan IV staining. Results: One week after ligation of the femoral artery a significant increase in collateral conductance was observed in animals treated with high dose MCP-1 (control: 2.2±0.8 ml/min/100 mmHg vs. MCP-1 high dose: 8.9±2.0 ml/min/100 mmHg, P<0.05). Six months after femoral artery ligation no differences were found between the treated and the control group (PBS; 44.9±11.6 ml/min/100 mmHg, MCP-1; 47.8±11.5 ml/min/100 mmHg, P = NS). No influence was found on serum lipids or on the development of atherosclerosis in the present model. Conclusion: MCP-1 accelerates arteriogenesis upon femoral artery ligation under hyperlipidemic conditions. Six months after treatment these pro-arteriogenic effects of MCP-1 can no longer be observed. The present data do not show an effect of local MCP-1 treatment on serum lipids or on atherosclerosis. It should be noted however that a high standard deviation was observed for the data on atherosclerotic surface area, necessitating additional experiments in a different model of atherosclerosis.

KEYWORDS Atherosclerosis; Collateral circulation; Cytokines; Hemodynamics; Macrophages


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
P. Meier, S. Gloekler, S. F. de Marchi, A. Indermuehle, T. Rutz, T. Traupe, H. Steck, R. Vogel, and C. Seiler
Myocardial Salvage Through Coronary Collateral Growth by Granulocyte Colony-Stimulating Factor in Chronic Coronary Artery Disease: A Controlled Randomized Trial
Circulation, October 6, 2009; 120(14): 1355 - 1363.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen
Stimulation of collateral artery growth: travelling further down the road to clinical application
Heart, February 1, 2009; 95(3): 191 - 197.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. L. Duvall, D. Weiss, S. T. Robinson, F. M.F. Alameddine, R. E. Guldberg, and W. R. Taylor
The Role of Osteopontin in Recovery from Hind Limb Ischemia
Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 290 - 295.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Gray, I. M. Packham, F. Wurmser, N. C. Eastley, P. G. Hellewell, P. W. Ingham, D. C. Crossman, and T. J.A. Chico
Ischemia Is Not Required for Arteriogenesis in Zebrafish Embryos
Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2135 - 2141.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Thalmann and C. A. Meier
Local adipose tissue depots as cardiovascular risk factors
Cardiovasc Res, September 1, 2007; 75(4): 690 - 701.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. Kupatt, R. Hinkel, M.-L. von Bruhl, T. Pohl, J. Horstkotte, P. Raake, C. El Aouni, E. Thein, S. Dimmeler, O. Feron, et al.
Endothelial Nitric Oxide Synthase Overexpression Provides a Functionally Relevant Angiogenic Switch in Hibernating Pig Myocardium
J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1575 - 1584.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. W. Chittenden, J. A. Sherman, F. Xiong, A. E. Hall, A. A. Lanahan, J. M. Taylor, H. Duan, J. D. Pearlman, J. H. Moore, S. M. Schwartz, et al.
Transcriptional Profiling in Coronary Artery Disease: Indications for Novel Markers of Coronary Collateralization
Circulation, October 24, 2006; 114(17): 1811 - 1820.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Zentilin, S. Tafuro, S. Zacchigna, N. Arsic, L. Pattarini, M. Sinigaglia, and M. Giacca
Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels
Blood, May 1, 2006; 107(9): 3546 - 3554.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
O. Awad, E. I. Dedkov, C. Jiao, S. Bloomer, R. J. Tomanek, and G. C. Schatteman
Differential Healing Activities of CD34+ and CD14+ Endothelial Cell Progenitors
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 758 - 764.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. F. Charo and M. B. Taubman
Chemokines in the Pathogenesis of Vascular Disease
Circ. Res., October 29, 2004; 95(9): 858 - 866.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Urbich and S. Dimmeler
Endothelial Progenitor Cells: Characterization and Role in Vascular Biology
Circ. Res., August 20, 2004; 95(4): 343 - 353.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett
Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis
Circulation, June 15, 2004; 109(23): 2826 - 2831.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. E. Kershaw and J. S. Flier
Adipose Tissue as an Endocrine Organ
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2548 - 2556.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Urbich, C. Heeschen, A. Aicher, E. Dernbach, A. M. Zeiher, and S. Dimmeler
Relevance of Monocytic Features for Neovascularization Capacity of Circulating Endothelial Progenitor Cells
Circulation, November 18, 2003; 108(20): 2511 - 2516.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.